Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biomarker development in the precision medicine era: lung cancer as a case study.

Literature DB >> 27388699

Biomarker development in the precision medicine era: lung cancer as a case study.

Abstract

Precision medicine relies on validated biomarkers with which to better classify patients by their probable disease risk, prognosis and/or response to treatment. Although affordable 'omics'-based technology has enabled faster identification of putative biomarkers, the validation of biomarkers is still stymied by low statistical power and poor reproducibility of results. This Review summarizes the successes and challenges of using different types of molecule as biomarkers, using lung cancer as a key illustrative example. Efforts at the national level of several countries to tie molecular measurement of samples to patient data via electronic medical records are the future of precision medicine research.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Biomarkers, Tumor

Year: 2016 PMID： 27388699 PMCID： PMC6662593 DOI： 10.1038/nrc.2016.56

Source DB: PubMed Journal: Nat Rev Cancer ISSN： 1474-175X Impact factor: 60.716

153 in total

Review 1. Phases of biomarker development for early detection of cancer.

Authors: M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui
Journal: J Natl Cancer Inst Date: 2001-07-18 Impact factor: 13.506

2. Serum metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time-of-flight mass spectrometry.

Authors: Yanjie Li; Xue Song; Xinjie Zhao; Lijuan Zou; Guowang Xu
Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2014-05-02 Impact factor: 3.205

Review 3. Emerging applications of metabolomics in drug discovery and precision medicine.

Authors: David S Wishart
Journal: Nat Rev Drug Discov Date: 2016-03-11 Impact factor: 84.694

4. Annual number of lung cancer deaths potentially avertable by screening in the United States.

Authors: Jiemin Ma; Elizabeth M Ward; Robert Smith; Ahmedin Jemal
Journal: Cancer Date: 2013-02-25 Impact factor: 6.860

5. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors: Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson
Journal: Cell Date: 2012-09-14 Impact factor: 41.582

6. The potential role of lung microbiota in lung cancer attributed to household coal burning exposures.

Authors: H Dean Hosgood; Amy R Sapkota; Nathaniel Rothman; Thomas Rohan; Wei Hu; Jun Xu; Roel Vermeulen; Xingzhou He; James Robert White; Guoping Wu; Fusheng Wei; Emmanuel F Mongodin; Qing Lan
Journal: Environ Mol Mutagen Date: 2014-06-03 Impact factor: 3.216

7. Passing messages between biological networks to refine predicted interactions.

Authors: Kimberly Glass; Curtis Huttenhower; John Quackenbush; Guo-Cheng Yuan
Journal: PLoS One Date: 2013-05-31 Impact factor: 3.240

8. Objective measurement and clinical significance of TILs in non-small cell lung cancer.

Authors: Kurt A Schalper; Jason Brown; Daniel Carvajal-Hausdorf; Joseph McLaughlin; Vamsidhar Velcheti; Konstantinos N Syrigos; Roy S Herbst; David L Rimm
Journal: J Natl Cancer Inst Date: 2015-02-03 Impact factor: 11.816

9. Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer.

Authors: Soojung Hong; Young Ae Kang; Byoung Chul Cho; Dae Joon Kim
Journal: Yonsei Med J Date: 2012-01 Impact factor: 2.759

10. Assessing the clinical utility of cancer genomic and proteomic data across tumor types.

Authors: Yuan Yuan; Eliezer M Van Allen; Larsson Omberg; Nikhil Wagle; Ali Amin-Mansour; Artem Sokolov; Lauren A Byers; Yanxun Xu; Kenneth R Hess; Lixia Diao; Leng Han; Xuelin Huang; Michael S Lawrence; John N Weinstein; Josh M Stuart; Gordon B Mills; Levi A Garraway; Adam A Margolin; Gad Getz; Han Liang
Journal: Nat Biotechnol Date: 2014-06-22 Impact factor: 54.908

159 in total

Review 1. A systems approach to clinical oncology uses deep phenotyping to deliver personalized care.

Authors: James T Yurkovich; Qiang Tian; Nathan D Price; Leroy Hood
Journal: Nat Rev Clin Oncol Date: 2019-10-16 Impact factor: 66.675

2. Distinguishing Rectal Cancer from Colon Cancer Based on the Support Vector Machine Method and RNA-sequencing Data.

Authors: Yan Zhang; Yuan Wu; Zi-Ying Gong; Hai-Dan Ye; Xiao-Kai Zhao; Jie-Yi Li; Xiao-Mei Zhang; Sheng Li; Wei Zhu; Mei Wang; Ge-Yu Liang; Yun Liu; Xin Guan; Dao-Yun Zhang; Bo Shen
Journal: Curr Med Sci Date: 2021-04-20

3. Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non-Small Cell Lung Cancer.

Authors: Yanxi Han; Rui Zhang; Guigao Lin; Kuo Zhang; Jiehong Xie; Jinming Li
Journal: Oncologist Date: 2017-07-12

4. Lung Cancer Field Cancerization: Implications for Screening by Low-Dose Computed Tomography.

Authors: Ana I Robles; Curtis C Harris
Journal: J Natl Cancer Inst Date: 2017-07-01 Impact factor: 13.506

5. Precision medicine with electronic medical records: from the patients and for the patients.

Authors: Losiana Nayak; Indrani Ray; Rajat K De
Journal: Ann Transl Med Date: 2016-10

6. A novel biomarker protein panel for lung cancer, a promising first step.

Authors: Camilo Molina-Romero; Edgar Vergara; Oscar Arrieta
Journal: Transl Lung Cancer Res Date: 2018-12

7. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.

Authors: Elena Martínez-Terroba; Carmen Behrens; Fernando J de Miguel; Jackeline Agorreta; Eduard Monsó; Laura Millares; Cristina Sainz; Miguel Mesa-Guzman; José Luis Pérez-Gracia; María Dolores Lozano; Javier J Zulueta; Ruben Pio; Ignacio I Wistuba; Luis M Montuenga; María J Pajares
Journal: J Pathol Date: 2018-06-20 Impact factor: 7.996